Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma
Authors:
- Derek K ChuDCDerek K Chu
- Amal Al-GarawiAAAmal Al-Garawi
- Alba Llop-GuevaraALAlba Llop-Guevara
- Regina A PillaiRPRegina A Pillai
- Katherine RadfordKRKatherine Radford
- Pamela ShenPSPamela Shen
- Tina D WalkerTWTina D Walker
- Susanna GoncharovaSGSusanna Goncharova
- William J CalhounWCWilliam J Calhoun
- Parameswaran NairPNParameswaran Nair
- Manel JordanaMJManel Jordana
Open Access
- 12 April 2015
- journal article
- research article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 11 (1) , 1-6
Abstract
Determining the cellular and molecular phenotypes of inflammation in asthma can identify patient populations that may best benefit from targeted therapies. Although elevated IL-6 and polymorphisms in IL-6 signalling are associated with lung dysfunction in asthma, it remains unknown if elevated IL-6 levels are associated with a specific cellular inflammatory phenotype, and how IL-6 blockade might impact such inflammatory responses. Patients undergoing exacerbations of asthma were phenotyped according to their airway inflammatory characteristics (normal cell count, eosinophilic, neutrophilic, mixed granulocytic), sputum cytokine profiles, and lung function. Mice were exposed to the common allergen, house dust-mite (HDM), in the presence or absence of endogenous IL-6. The intensity and nature of lung inflammation, and levels of pro-granulocytic cytokines and chemokines under these conditions were analyzed. Elevated IL-6 was associated with a lower FEV1 in patients with mixed eosinophilic-neutrophilic bronchitis. In mice, allergen exposure increased lung IL-6 and IL-6 was produced by dendritic cells and alveolar macrophages. Loss-of-function of IL-6 signalling (knockout or antibody-mediated neutralization) abrogated elevations of eosinophil and neutrophil recruiting cytokines/chemokines and allergen-induced airway inflammation in mice. We demonstrate the association of pleiotropic cellular airway inflammation with IL-6 using human and animal data. These data suggest that exacerbations of asthma, particularly those with a combined eosinophilic and neutrophilic bronchitis, may respond to therapies targeting the IL-6 pathway and therefore, provide a rational basis for initiation of clinical trials to evaluate this.Keywords
This publication has 22 references indexed in Scilit:
- A GM-CSF/IL-33 Pathway Facilitates Allergic Airway Responses to Sub-Threshold House Dust Mite ExposurePLOS ONE, 2014
- Targeted therapy of bronchitis in obstructive airway diseasesPharmacology & Therapeutics, 2013
- Update on Clinical Inflammometry for the Management of Airway DiseasesCanadian Respiratory Journal, 2013
- Interleukin-6: from an inflammatory marker to a target for inflammatory diseasesTrends in Immunology, 2012
- The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthmaJournal of Allergy and Clinical Immunology, 2012
- Sputum IL-6 concentrations in severe asthma and its relationship with FEV1Thorax, 2010
- The molecular phenotype of severe asthma in childrenJournal of Allergy and Clinical Immunology, 2010
- Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway functionRespiratory Research, 2010
- IL-6 Is Required for Airway Mucus Production Induced by Inhaled Fungal AllergensThe Journal of Immunology, 2009
- Circulating Levels of Soluble Interleukin-6 Receptor in Patients with Bronchial AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1997